Form 4: United Therapeutics EVP Paul Mahon Executes Stock Sale

EVP and General Counsel Paul Mahon exercised 8,300 stock options and sold the resulting shares under a 10b5-1 trading plan.

Summary

• Paul A. Mahon, EVP and General Counsel of United Therapeutics Corporation, exercised 8,300 stock options at a strike price of $146.03.
• Following the exercise, the reporting person sold the 8,300 shares in multiple tranches at weighted average prices ranging from $574.03 to $578.21.
• The transactions were conducted pursuant to a pre-arranged Rule 10b5-1 trading plan established on August 11, 2025.
• The reporting person's direct beneficial ownership of common stock stands at 45,172 shares following these transactions.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the sale was conducted under a pre-arranged 10b5-1 plan, which is a standard mechanism for executive financial planning.

Positives

• The transaction was executed under a pre-arranged 10b5-1 plan, indicating the sale was planned in advance rather than based on immediate non-public information.

Negatives

• The transaction represents a reduction in the executive's direct equity stake in the company.

Risks

• None identified in this filing.

Future Outlook

Not applicable; this is a routine disclosure of insider transaction activity.

Industry Context

StockSavvy.ai notes that routine insider selling via 10b5-1 plans is a standard practice for corporate executives to manage personal liquidity and is generally viewed as neutral by the market.

Comparison to Industry Standards

• The use of 10b5-1 plans is the industry standard for executives to avoid potential conflicts of interest regarding insider trading regulations.

Stakeholder Impact

• Minimal impact on shareholders as the transaction was pre-planned and represents a small portion of the executive's total holdings.

Key Dates

Keywords

United Therapeutics, UTHR, Insider Trading, Form 4, Stock Option Exercise, 10b5-1 Plan